NIH-funded research NIH-funded research

Understanding Environmental Factors for Children's Health

Official title: Enriching ECHO Cohorts with High-risk Pregnancies and Children with Health Challenges (Enriching ECHO)

Funded at Hackensack University Medical Center · NIH-11319090 · Data updated 2026-11-12

This project aims to understand how environmental factors and personal choices during and after pregnancy affect the health and well-being of children, especially those facing health challenges.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionHackensack University Medical Center
NIH-funded
Lab location1 site (Hackensack, United States)
Project startSeptember 1, 2023
Project endMay 31, 2030
Funding year2025
Award (this year)$5,019,949
NIH project number4UH3OD035546-03
Project IDNIH-11319090 on NIH RePORTER

Who could benefit from this research

Could help

Ideal participants would include pregnant individuals identified as high-risk and families with children who have physical, sensory, or developmental challenges.

Less likely to help

Patients who are not pregnant or do not have children within the specified age range or health conditions would not directly benefit from participating in this specific cohort.

What this research studies

We want to learn how different things in a child's environment, both before and after birth, influence their health as they grow up. This includes looking at how factors like parenting styles and social support might help children with ongoing health issues thrive. Our goal is to find specific, changeable factors that can lead to better health outcomes for all children, particularly those with physical, sensory, or developmental challenges. We plan to recruit pregnant individuals at higher risk and work with communities to ensure our approach is helpful and inclusive.

Why it matters

Potential benefit: This work could help identify ways to support children with health challenges and promote positive health for all children throughout their lives.

How similar studies have gone: This project builds upon existing research within the ECHO program by specifically focusing on high-risk pregnancies and children with health challenges to identify new modifiable factors.

Where this research is happening

  • Hackensack University Medical Center
    Hackensack, United States
    Active

Researchers

  • Principal investigator: Aschner, Judy Lynn — Hackensack University Medical Center
  • Study coordinator: Aschner, Judy Lynn

Related research

Other NIH-funded projects on the same topics.

  • Orally accessible antiviral leaders to fight COVID-19 and related coronaviruses

    A research effort to fast-track safe, easy-to-take oral drugs that can treat COVID-19 and other coronaviruses by repurposing and optimizing existing antiviral compounds.

    NIH research Hackensack University Medical Center · Hackensack, United States · NIH-11619619

  • Metropolitan Antiviral Drug Accelerator Virology Core

    A core team across top hospitals and universities is testing antiviral compounds against SARS-CoV-2 and related coronaviruses to identify promising drugs for COVID-19.

    NIH research Hackensack University Medical Center · Hackensack, United States · NIH-11617048

  • Broad-spectrum SARS-CoV-2 protease inhibitor for antiviral therapy

    Researchers are developing a new small-molecule drug that blocks a key SARS-CoV-2 enzyme, with potential to treat COVID-19 across multiple virus variants.

    NIH research Hackensack University Medical Center · Hackensack, United States · NIH-11617047

  • Metropolitan AntiViral Drug Accelerator: Animal Models

    A large NIH-funded effort uses animal models to test new antiviral compounds against SARS-CoV-2 and related viruses to move promising leads toward early development.

    NIH research Hackensack University Medical Center · Hackensack, United States · NIH-11617032

  • Metropolis AntiViral Drug Accelerator: Pharmacology Core

    A dedicated program to speed up promising antiviral drugs by testing their behavior in the body and choosing the best candidates for further development.

    NIH research Hackensack University Medical Center · Hackensack, United States · NIH-11617031

  • Metropolitan Antiviral Drug Accelerator

    A national program at Hackensack University Medical Center to help develop and optimize small-molecule drugs that may block key SARS-CoV-2 proteins, potentially slowing COVID-19 replication.

    NIH research Hackensack University Medical Center · Hackensack, United States · NIH-11617030

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.